The Biomedical & Life Sciences Collection hosts a series of live immunology webinars.
Registration for upcoming events is free and recordings of all past events are available.View All
John Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. Dr. Hardy received his B.Sc. (Hons) degree from the University of Leeds, UK (1976) and his Ph.D. from Imperial College, London, UK where he studied dopamine and amino acid neuropharmacology. Dr. Hardy received his postdoctoral... read moretraining at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, UK and then further postdoctoral work at the Swedish Brain Bank in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College, London in 1985 and initiated genetic studies of Alzheimer’s disease whilst there. He was appointed Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to the Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to NIA as Chief of the Laboratory of Neurogenetics in 2001. He won the MetLife, the Allied Signal and the Potamkin Prize for his work in describing the first genetic mutations, in the amyloid gene in Alzheimer’s disease, in 1991. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimer's disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009. In 2016 Prof Hardy received the Breakthrough Prize in Life Sciences for his research on the cause of early-onset Alzheimer’s disease.